Global pharma major Lupin Limited (Lupin) today announced the launch of Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, having received an approval from the United States Food and Drug Administration (US FDA). The product is manufactured at Lupin's facility in Nagpur, India.
Droxidopa Capsules, 100 mg, 200 mg, and 300 mg is a generic equivalent of Northera® Capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA Ltd., indicated for the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
Droxidopa Capsules (RLD: Northera®) had estimated annual sales of USD 294 million in the U.S. (IQVIA MAT July 2021).
Shares of Lupin Ltd was last trading in BSE at Rs. 948.9 as compared to the previous close of Rs. 936.35. The total number of shares traded during the day was 99392 in over 4932 trades.
The stock hit an intraday high of Rs. 953.5 and intraday low of 928.4. The net turnover during the day was Rs. 93611163.